Insider Trading June 16, 2026 04:57 PM

Omada Health President Executes Stock Sale Under Pre-Arranged Plan

Shao Wei-Li disposes of 4,589 shares, reducing direct holdings as digital health firm reports Q1 earnings beat and analyst upgrade

By Caleb Monroe
Share
Twitter Reddit Facebook LinkedIn
OMDA

Omada Health President Shao Wei-Li sold 4,589 shares of the company's common stock on June 12, 2026, realizing proceeds of $79,117. The transaction was executed at a weighted average price of $17.2407 per share, with prices ranging from $17.10 to $17.54. This sale was conducted under a pre-arranged 10b5-1 trading plan established on March 13, 2026. Following the transaction, Shao Wei-Li directly holds 316,238 shares of Omada Health common stock.

Omada Health President Executes Stock Sale Under Pre-Arranged Plan
OMDA
Summarize with
ChatGPT Perplexity Claude Grok Gemini

Key Points

  • Shao Wei-Li sold 4,589 shares at a weighted average price of $17.2407, with a total value of $79,117, under a pre-arranged 10b5-1 trading plan adopted on March 13, 2026.
  • Omada Health reported a Q1 2026 EPS of -$0.05, beating the forecasted -$0.08, with revenue of $78 million, representing a 42% year-over-year growth.
  • Citizens raised its price target for Omada Health to $21 from $18, citing a positive growth outlook and noting the stock trades at 2.5 times the firm's 2026 revenue estimate.

Shao Wei-Li, serving as President of Omada Health, Inc. (NASDAQ:OMDA), executed a sale of 4,589 shares of the company's common stock on June 12, 2026. The total value of the shares sold amounted to $79,117. The shares were sold at a weighted average price of $17.2407 per share. The transactions occurred at prices ranging from $17.10 to $17.54. This sale was conducted pursuant to a pre-arranged 10b5-1 trading plan, which Shao Wei-Li adopted on March 13, 2026.

Following this transaction, Mr. Shao directly holds 316,238 shares of Omada Health common stock. The sale comes as Omada Health trades near $17.10, with the stock delivering an 18.62% return over the past six months. According to InvestingPro analysis, the company appears overvalued at current levels. The digital health company, valued at $1.03 billion, generated $283.3 million in revenue with notable 49% growth. For deeper insights into OMDA's valuation and growth prospects, investors can access the comprehensive Pro Research Report, available for this and 1,400+ other US equities.

In other recent news, Omada Health Inc. reported its financial results for the first quarter of 2026, showcasing a positive earnings surprise. The company achieved an EPS of -$0.05, which surpassed the forecasted -$0.08. Omada Health's revenue reached $78 million, reflecting a 42% year-over-year growth. Following these results, Citizens raised its price target for Omada Health to $21 from $18, maintaining a Market Outperform rating. The analyst from Citizens, Constantine Davides, highlighted that Omada Health recently traded at 2.5 times the firm's 2026 revenue estimate. This adjustment in the price target reflects a positive growth outlook for the company. These developments indicate a robust financial performance and optimistic investor sentiment.

Omada Health

Follow

Analyze OMDA

Included in our AI-picked strategies

Review strategies

17.10

▼-0.23

(-1.33%)

Closed

·15:59:59

·USD

17.11

0.00

(0.00%)

After Hours

·16:28:31

1D

1W

1M

6M

1Y

5Y

Max

Created with Highcharts 11.4.8

14:00

15:00

16:00

17:00

18:00

19:00

16.75

17

17.25

17.5

Analyze OMDA

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Spot the trade on OMDA before it happens

Most traders know the market. The hard part is the moment — which stock, right now, at what price.

Chart analysis handles that.

Our Vision AI scans your charts, spots the pattern before it plays out, and hands you the complete setup: entry, exit, done in under 60 seconds. Investors are already reporting a high accuracy rate, even on penny stocks.

Flash Sale - Price Goes Up Soon

Risks

  • InvestingPro analysis suggests the company appears overvalued at current levels, indicating potential valuation risks for investors.
  • The sale of shares by the President, while conducted under a pre-arranged plan, may signal internal profit-taking or liquidity management, which could impact market perception.
  • The digital health sector remains subject to regulatory and competitive pressures, though the article does not explicitly detail these risks beyond the valuation concern.

More from Insider Trading

Ra Capital Management Cuts Werewolf Therapeutics Holding by $173,757 Jun 16, 2026 Global GP LLC Acquires Units Amid Stock Decline and Earnings Surprise Jun 16, 2026 Suzanne Helen Disposes of $637K in Mohawk Industries Shares Ahead of Leadership Transition Jun 16, 2026 Via Transportation CFO Clara Fain Buys $19,986 in Company Stock Amid Market Decline Jun 16, 2026 Joby Aviation Executive Papadopoulos Sells Shares Amidst Ongoing Certification Investments Jun 16, 2026